Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib (HM43239) for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Presentations

News

News

  • Press Releases
  • Presentations
  • Events
2019 ESH Poster - CG-806 Pan-FLT3/Pan-BTK Inhibitor Simultaneously Suppresses Multiple Oncogenic Signaling Pathways to Treat AML

2019 ESH Poster - CG-806 Pan-FLT3/Pan-BTK Inhibitor Simultaneously Suppresses Multiple Oncogenic Signaling Pathways to Treat AML

Oct 24, 2019
2019 EHA Poster - CG-806, PRECLINICAL IN VIVO EFFICACY AND SAFETY PROFILE AS A PAN-FLT3 / PAN-BTK INHIBITOR

2019 EHA Poster - CG-806, PRECLINICAL IN VIVO EFFICACY AND SAFETY PROFILE AS A PAN-FLT3 / PAN-BTK INHIBITOR

Jun 14, 2019
24th Congress of The European Hematology Association 2019 - CG-806, Preclinica…

24th Congress of The European Hematology Association 2019 - CG-806, Preclinica…

May 16, 2019
2019 AACR Poster - Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in Raji B cells

2019 AACR Poster - Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in Raji B cells

Apr 1, 2019
2019 AACR Poster - CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients

2019 AACR Poster - CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients

Apr 1, 2019
Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers

Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers

Dec 12, 2018
2018 ASH Poster – CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

2018 ASH Poster – CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

Dec 2, 2018
2018 ASH Poster – Concomitant Targeting of FLT3 and BTK with CG-806 Overcomes FLT3-Inhibitor Resistance Through Inhibition of Autophagy

2018 ASH Poster – Concomitant Targeting of FLT3 and BTK with CG-806 Overcomes FLT3-Inhibitor Resistance Through Inhibition of Autophagy

Dec 2, 2018
2018 EHA Poster - CG-806, a Non Covalent Pan-FLT3/Pan-BTK Inhibitor, Exhibits Unique Binding to Wild Type and C481S Mutant BTK and Greater Potency Than Ibrutinib Against Malignant B Cells

2018 EHA Poster - CG-806, a Non Covalent Pan-FLT3/Pan-BTK Inhibitor, Exhibits Unique Binding to Wild Type and C481S Mutant BTK and Greater Potency Than Ibrutinib Against Malignant B Cells

Jun 15, 2018
2018 AACR Poster - APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency

2018 AACR Poster - APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency

Apr 17, 2018
RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »
© 2023 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap